Forte Biosciences, Inc.

Clinical-stage biopharmaceutical company developing FB102, a proprietary anti-CD122 monoclonal antibody for autoimmune and autoimmune-related diseases such as celiac disease. Headquartered in Dallas, Texas (Nasdaq: FBRX).